Diovan, Valsartan News

Novartis AG is expanding its cardiovascular disease therapy pipeline through its acquisition of San Mateo, Calif.-based biotech Corthera Inc., giving the Swiss pharma giant exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide currently in Phase III development as a treatment for acute decompensated ...

Novartis could find its leadership position in blood pressure therapies challenged in the next two years, owing to generic intrusion on its flagship anti-hypertensive drug Diovan .

Q: I heard about a new combination drug for high blood pressure. What can you tell me about it? A: High blood pressure or hypertension is a very common problem that affects about 50 million people the United States, and nearly one-third of them don't know they have it.

Basel, - The European Commission has granted Novartis marketing authorization for Exforge HCT , a new 3-in-1 treatment for people with high blood pressure.

The drug is a single-pill combination of valsartan and aliskiren. Valsartan is the active ingredient in Novartis' high blood pressure drug Diovan while aliskiren is the active ingredient in the company's blood pressure drug Tekturna.

The FDA has approved Novartis ' Valturna tablets, a medicine targeting two key points within the renin system, also known as the renin angiotensin aldosterone system , a regulator of blood pressure.

The US Food and Drug Administration has approved Valturna ) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system , an important regulator of blood pressure.

Main Category: Cardiovascular / Cardiology Also Included In: Heart Disease Article Date: 02 Sep 2009 - 2:00 PDT Data confirm that in heart failure patients being treated with ACE inhibitor and/or beta blocker, higher plasma renin activity still predicts greater risk of mortality1.

Data presented at the 19th Scientific Meeting of the European Society of Hypertension confirm that Diovan and valsartan-based combinations deliver sustained, 24-hr blood pressure -lowering efficacy2-6. Studies have suggested that the relative risks of acute myocardial infarction, stroke and sudden cardiac death are 40%, 49% and 29% higher, ...